Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling

Hsu,Fei-Ting; Liu,Yu-Chang; Chiang,I-Tsang; Liu,Ren-Shyan; Wang,Hsin-Ell; Lin,Wuu-Jyh; Hwang,Jeng-Jong

doi:10.3892/ijo.2014.2423

Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling

Authors:
- Fei-Ting Hsu
- Yu-Chang Liu
- I-Tsang Chiang
- Ren-Shyan Liu
- Hsin-Ell Wang
- Wuu-Jyh Lin
- Jeng-Jong Hwang
View Affiliations

Affiliations: Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei 112, Taiwan, R.O.C., Department of Radiation Oncology, National Yang-Ming University Hospital, Yilan 260, Taiwan, R.O.C., Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan, R.O.C., Division of Radioisotope, Institute of Nuclear Energy Research, Taoyuan 32546, Taiwan, R.O.C.
Published online on: May 6, 2014 https://doi.org/10.3892/ijo.2014.2423
Pages: 177-188

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemoembolization. The survival benefit of sorafenib, however, is unsatisfactory. Vorinostat also known as suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase (HDAC) inhibitor with anti-HCC efficacy in preclinical studies. SAHA induces nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) activity in vitro, which may lead to cancer cell progression and jeopardize cytotoxic effect of SAHA in HCC. The goal of this study was to investigate whether sorafenib enhances SAHA cytotoxicity against HCC through inhibition of SAHA-induced NF-κB activity. The human HCC cell line Huh7 transfected with dual reporter genes, luciferase (luc) and thymidine kinase (tk) with NF-κB response elements, was co-transfected with red fluorescent protein (rfp) gene for non-invasive molecular imaging to assess NF-κB activity and living cells simultaneously. Cell viability assay, DNA fragmentation, western blotting, electrophoretic mobility shift assay (EMSA) and multiple modalities of molecular imaging were used to assess the combination efficacy and mechanism of sorafenib and SAHA. The administration of high-dose SAHA (10 µM) with long treatment time (48 h) in vitro, and 25 mg/kg/day by gavage in HCC-bearing nude mice to induce NF-κB activity were performed. Sorafenib inhibited SAHA-induced NF-κB activity and the expression of NF-κB-regulated effector proteins while it increased the efficacy of SAHA against HCC both in vitro and in vivo. The mechanism of sorafenib to enhance SAHA efficacy on HCC is through the suppression of ERK/NF-κB pathway, which induces extrinsic and intrinsic apoptosis. Combination of sorafenib and SAHA may have the potential as new strategy against HCC.

View Figures

View References

1.	Feng M and Ben-Josef E: Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 21:271–277. 2011. View Article : Google Scholar
2.	Zhang X, Yang XR, Huang XW, et al: Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 11:458–466. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Kanno K, Kanno S, Nitta H, et al: Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep. 28:867–873. 2012.PubMed/NCBI
4.	Wu J, Du C, Lv Z, et al: The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci. 58:3545–3553. 2013. View Article : Google Scholar : PubMed/NCBI
5.	Rikimaru T, Taketomi A, Yamashita Y, et al: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 72:69–74. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Wu LM, Yang Z, Zhou L, et al: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 5:e144602010. View Article : Google Scholar : PubMed/NCBI
7.	Machado MC, Bellodi-Privato M, Kubrusly MS, et al: Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol. 9:85–92. 2011.PubMed/NCBI
8.	Coradini D and Speranza A: Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin. 26:1025–1033. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Yoshida K, Sasaki R, Nishimura H, et al: Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck. 32:646–655. 2010.PubMed/NCBI
10.	Ni W, Chen B, Zhou G, et al: Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. J Cell Biochem. 114:2120–2130. 2013. View Article : Google Scholar : PubMed/NCBI
11.	Zhang G, Park MA, Mitchell C, et al: Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res. 14:5385–5399. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Spratlin JL, Pitts TM, Kulikowski GN, et al: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 31:1093–1103. 2011.PubMed/NCBI
13.	Wang WH, Chiang IT, Liu YC, et al: Simultaneous imaging of temporal changes of NF-kappaB activity and viable tumor cells in Huh7/NF-kappaB-tk-luc2/rfp tumor-bearing mice. In vivo. 27:339–350. 2013.PubMed/NCBI
14.	Dai Y, Rahmani M, Dent P and Grant S: Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol. 25:5429–5444. 2005. View Article : Google Scholar
15.	Domingo-Domenech J, Pippa R, Tapia M, Gascon P, Bachs O and Bosch M: Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat. 112:53–62. 2008. View Article : Google Scholar
16.	Dai Y, Guzman ML, Chen S, et al: The NF (nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol. 151:70–83. 2010. View Article : Google Scholar
17.	Dai Y, Chen S, Wang L, et al: Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem. 286:34036–34050. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Schelman WR, Traynor AM, Holen KD, et al: A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 31:1539–1546. 2013. View Article : Google Scholar : PubMed/NCBI
19.	Deming DA, Ninan J, Bailey HH, et al: A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 32:323–329. 2014. View Article : Google Scholar : PubMed/NCBI
20.	Liu YC, Chiang IT, Hsu FT and Hwang JJ: Using NF-kappaB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn. 12:139–146. 2012. View Article : Google Scholar
21.	Chiang IT, Liu YC, Wang WH, et al: Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-kappaB pathway in hepatocellular carcinoma cells. In vivo. 26:671–681. 2012.
22.	Bankston D, Dumas J, Natero R, et al: A scaleable synthesis of BAY 43-9006 a potent Raf kinase inhibitor for the treatment of cancer. Org Process Res Dev. 6:777–781. 2002. View Article : Google Scholar
23.	Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Li F and Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
25.	Galimberti S, Canestraro M, Khan R, et al: Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia. 22:628–631. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem. 281:5612–5622. 2006. View Article : Google Scholar
27.	Chen KF, Chen HL, Tai WT, et al: Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharm Exp Ther. 337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
28.	Park MA, Zhang G, Martin AP, et al: Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 7:1648–1662. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Park MA, Mitchell C, Zhang G, et al: Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 70:6313–6324. 2010.PubMed/NCBI
30.	Dasari A, Gore L, Messersmith WA, et al: A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 31:115–125. 2013. View Article : Google Scholar : PubMed/NCBI
31.	Warlick ED, Cao Q and Miller J: Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodys-plastic syndromes: produces stable disease but at the cost of high toxicity. Leukemia. 27:1789–1791. 2013. View Article : Google Scholar : PubMed/NCBI
32.	Hoang T, Campbell TC, Zhang C, et al: Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs. 32:195–199. 2014. View Article : Google Scholar : PubMed/NCBI
33.	Friday BB, Anderson SK, Buckner J, et al: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 14:215–221. 2012. View Article : Google Scholar : PubMed/NCBI